Equities analysts expect that Insulet Co. (NASDAQ:PODD) will report earnings of $0.09 per share for the current quarter, Zacks reports. Nine analysts have made estimates for Insulet’s earnings, with estimates ranging from ($0.02) to $0.27. Insulet reported earnings of $0.16 per share during the same quarter last year, which suggests a negative year-over-year growth rate of 43.8%. The firm is expected to report its next quarterly earnings report on Monday, February 24th.

On average, analysts expect that Insulet will report full year earnings of $0.18 per share for the current fiscal year, with EPS estimates ranging from $0.09 to $0.28. For the next fiscal year, analysts forecast that the business will post earnings of $0.69 per share, with EPS estimates ranging from $0.32 to $1.08. Zacks Investment Research’s EPS calculations are an average based on a survey of research firms that cover Insulet.

Insulet (NASDAQ:PODD) last posted its earnings results on Tuesday, November 5th. The medical instruments supplier reported $0.01 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.03 by ($0.02). The business had revenue of $192.12 million during the quarter, compared to analyst estimates of $179.50 million. Insulet had a net margin of 2.38% and a return on equity of 10.34%. Insulet’s revenue was up 27.2% compared to the same quarter last year. During the same quarter last year, the firm earned $0.03 earnings per share.

Several analysts have recently issued reports on the company. Svb Leerink upped their price target on Insulet from $160.00 to $185.00 and gave the stock an “outperform” rating in a research note on Tuesday, September 24th. Cowen set a $165.00 target price on Insulet and gave the stock a “buy” rating in a research report on Monday, October 21st. BTIG Research downgraded Insulet from a “buy” rating to a “neutral” rating in a report on Monday, October 14th. ValuEngine lowered shares of Insulet from a “buy” rating to a “hold” rating in a research report on Wednesday, October 2nd. Finally, Stifel Nicolaus began coverage on shares of Insulet in a research note on Tuesday, October 22nd. They issued a “hold” rating and a $163.00 price objective for the company. Nine research analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Insulet has an average rating of “Buy” and a consensus price target of $151.63.

NASDAQ:PODD traded up $1.56 during trading hours on Thursday, reaching $183.47. The company’s stock had a trading volume of 234,829 shares, compared to its average volume of 1,066,446. The company has a debt-to-equity ratio of 6.55, a current ratio of 7.01 and a quick ratio of 6.21. The company has a market cap of $11.48 billion, a price-to-earnings ratio of 3,669.30 and a beta of 1.04. Insulet has a one year low of $70.80 and a one year high of $187.25. The business’s 50-day moving average is $164.45 and its 200-day moving average is $140.82.

In other Insulet news, Director John A. Fallon sold 14,525 shares of the business’s stock in a transaction on Monday, November 18th. The shares were sold at an average price of $181.21, for a total value of $2,632,075.25. Also, CEO Shacey Petrovic sold 689 shares of the business’s stock in a transaction on Friday, November 1st. The shares were sold at an average price of $145.69, for a total transaction of $100,380.41. Following the completion of the sale, the chief executive officer now directly owns 94,510 shares in the company, valued at approximately $13,769,161.90. The disclosure for this sale can be found here. Company insiders own 3.50% of the company’s stock.

Several hedge funds have recently made changes to their positions in the company. Advisors Preferred LLC acquired a new stake in shares of Insulet during the 2nd quarter valued at about $38,000. Harvest Fund Management Co. Ltd acquired a new position in Insulet in the second quarter worth about $43,000. Mitsubishi UFJ Securities Holdings Co. Ltd. acquired a new position in Insulet in the second quarter worth about $97,000. Steward Partners Investment Advisory LLC bought a new position in Insulet during the second quarter worth about $119,000. Finally, Stifel Financial Corp bought a new position in Insulet during the third quarter worth about $204,000.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company offers Omnipod System, which consists of self-adhesive disposable tubeless Omnipod device (the pod) that delivers insulin into the body; and Personal Diabetes Manager, a handheld wireless device, which programs the Pod.

Featured Story: What does RSI mean?

Get a free copy of the Zacks research report on Insulet (PODD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Insulet (NASDAQ:PODD)

Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with MarketBeat.com's FREE daily email newsletter.